Therefore, as discussed above, pharmacological evidence from patient-derived SSL organoids and appropriate patient selection with aPKC, ANXA10/MUC5A, and SREBP2 supports future randomized controlled trials for serrated CRC chemoprevention. The gene discussed is SREBF2; the disease is colorectal carcinoma.